Novartis PTK/ZK 787 Data Presented At ASCO; Survival Analysis Pending
Further development of Novartis/Schering AG's colorectal cancer agent PTK/ZK 787 (vatalanib) should include optimizing the dosing schedule and identifying appropriate prognostic factors, a consultant suggested at the American Society of Clinical Oncology annual meeting
You may also be interested in...
Novartis/Schering AG may shift development of their investigational colorectal cancer agent PTK/ZK 787 (valatanib) to focus on patients with elevated lactate dehydrogenase (LDH) levels, Novartis Oncology President David Epstein said June 7
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011